New Commitments. Neither Party will incur new expenses related to this CRADA after expiration, mutual termination, or a notice of a unilateral termination and will, to the extent feasible, cancel all outstanding commitments and contracts by the termination date. Collaborator acknowledges that IC will have the authority to retain and expend any funds for up to [***] subsequent to the expiration or termination date to cover any unpaid costs obligated during the term of the CRADA in undertaking the research and development activities set forth in the Research Plan and for ongoing CRADA-related expenses that arise after the expiration or termination date, such as vaccine stability testing, managing or analyzing CRADA Data and CRADA Materials, continuing ongoing clinical trials, and conducting follow-up observations of Human Subjects treated under the CRADA, such that the authority to make these expenditures will survive the CRADA. [***] 6/25/13 [***] Date Deputy Director for Clinical and Translational Research, NCI [***] 28 May 2013 Name: [***] Date Title: President, BN Immunotherapeutics, Inc. The purpose of this amendment is to change certain terms of the above-referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below, and except for these changes, all other provisions of the original CRADA, as amended by Amendment #1 on June 21, 2013, remain in full force and effect. The Parties agree as follows:
Appears in 2 contracts
Sources: Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR), Cooperative Research and Development Agreement (Bavarian Nordic a/S / ADR)